Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 9/20 | 0.66 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.41 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.41 |
| ▸ | S100A9 | P06702 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4518089 | 0.82 | NR3C1 (0.67) | NR3C1HTTALDH1A1KMT2A | |
| SCHEMBL4501700 | 0.79 | NR3C1 (1.00) | NR3C1 | |
| SCHEMBL4517669 | 0.79 | NR3C1 (0.73) | NR3C1HTTALDH1A1 | |
| SCHEMBL4521905 | 0.79 | NR3C1 (0.74) | NR3C1 | |
| SCHEMBL4507730 | 0.78 | NR3C1 (0.66) | NR3C1ALDH1A1KMT2A | |
| SCHEMBL4517545 | 0.77 | NR3C1 (1.00) | NR3C1 | |
| SCHEMBL4501569 | 0.77 | NR3C1 (0.68) | NR3C1HTTALDH1A1DRD2KMT2A | |
| SCHEMBL4520346 | 0.77 | NR3C1 (0.67) | NR3C1HTTALDH1A1KMT2A | |
| SCHEMBL4515242 | 0.76 | NR3C1 (0.69) | NR3C1DRD2 | |
| SCHEMBL4501289 | 0.76 | NR3C1 (0.61) | NR3C1ALDH1A1DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090093485-A1 | Novel Sulphonamide Derivatives as Glucocorticoid Receptor Modulators for the Treatment of Inflammatory Diseases | ASTRAZENECA AB (SE) | 2009-04-09 | — | — | US | disclosed |
| US-20090093485-A1 | Novel Sulphonamide Derivatives as Glucocorticoid Receptor Modulators for the Treatment of Inflammatory Diseases | ASTRAZENECA AB (SE) | 2009-04-09 | — | — | US | disclosed |
| US-20090093485-A1 | Novel Sulphonamide Derivatives as Glucocorticoid Receptor Modulators for the Treatment of Inflammatory Diseases | ASTRAZENECA AB (SE) | 2009-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090093485-A1 | Novel Sulphonamide Derivatives as Glucocorticoid Receptor Modulators for the Treatment of Inflammatory Diseases | NR3C1, NR3C2, NR5A1 | NR3C1 1/4885HTT 3337/4885ALDH1A1 2398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.